What drove GV.PA stock activity today?

GV.PA stock activity stems from low share price and high trade volume; **38,489,238** shares traded today. Microcap liquidity, speculative orders, and occasional reprints of company news typically cause these intraday moves.

What is Meyka AI’s view on GV.PA stock forecast?

Meyka AI’s forecast model projects a 12‑month base case of **€0.0040**, implying **122.22%** upside from **€0.0018**. Forecasts are model projections and not guarantees; downside and dilution risk remain significant.

Should investors buy GV.PA stock now?

GV.PA stock is high risk. Meyka AI assigns a **B** grade with a HOLD suggestion. Active traders may exploit volatility; longer‑term investors should wait for revenue signs or stronger cash position before increasing exposure.

What financial metrics matter most for GV.PA stock?

Key metrics include EPS **-0.11**, price to sales **0.47**, cash per share **€0.00557**, current ratio **0.91**, and free cash flow negativity, which together indicate tight liquidity and ongoing operating losses.

EU Stocks

GV.PA stock trades €0.0018 on EURONEXT 10 Feb 2026: heavy volume signals short-term interest

ByDanny Kontos February 10, 2026February 10, 2026

GV.PA stock is the most active small-cap on EURONEXT intraday, trading at €0.0018 with a 5.88% rise and 38,489,238 shares exchanged so far. The surge lifts volume to 2.71x average, a notable liquidity spike for Genomic Vision SA (GV.PA). Traders are reacting to low float dynamics, continued negative EPS of -0.11, and very low market cap €693,191. We review intraday drivers, fundamentals, valuation and a model-based 12‑month forecast to frame risk and potential upside for Europe-listed Genomic Vision SA.